

# Effectiveness of Indapamide SR on top of Perindopril on blood pressure change: a methodological study to validate effect of anti-hypertensive drugs in CPRD Aurum.

**First published:** 22/12/2021

**Last updated:** 23/04/2024

Study

Ongoing

## Administrative details

### **PURI**

<https://redirect.ema.europa.eu/resource/44584>

---

### **EU PAS number**

EUPAS44583

---

### **Study ID**

44584

---

### **DARWIN EU® study**

No

---

## Study countries

United Kingdom

---

## Study description

Antihypertensive treatments efficacy is demonstrated in Randomized Controlled Trials (RCT) based on frequent, iterative BP measures while these measurements are sparse in real life setting. The aim of this study is to assess whether this efficacy can be objectivised using Blood Pressure (BP) records collected in routine practice. In a main approach, this study will emulate, using Clinical Research Practice Datalink, a theoretical phase III RCT comparing the BP changes when adding indapamide SR on top of perindopril 4/5mg versus staying on perindopril 4/5mg alone, in patients who have uncontrolled hypertension.

---

## Study status

Ongoing

## Research institutions and networks

### Institutions

[Institut de Recherches Internationales Servier](#)

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

## Contact details

### **Study institution contact**

Institut de Recherches Internationales Servier Institut de  
Recherches Internationales Servier

**Study contact**

[RWE.Dept@servier.com](mailto:RWE.Dept@servier.com)

### **Primary lead investigator**

Nadjat Mounedji

**Primary lead investigator**

## Study timelines

### **Date when funding contract was signed**

Planned: 01/09/2020

Actual: 01/09/2020

---

### **Study start date**

Planned: 14/06/2021

Actual: 14/06/2021

---

### **Data analysis start date**

Planned: 15/06/2021

Actual: 15/06/2021

---

### **Date of final study report**

Planned: 29/04/2022

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Institut de Recherches Internationales Servier

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

#### **Study type:**

Non-interventional study

---

#### **Scope of the study:**

Effectiveness study (incl. comparative)

#### **Main study objective:**

The overall aim of this study is to assess whether and how efficacy of antihypertensive therapy can be objectivised using Blood Pressure records

collected during routine clinical practice. In a main approach, the study will emulate a theoretical phase III study with the same antihypertensive treatments using the Clinical Research Practice Datalink (CPRD).

## Study Design

### **Non-interventional study design**

Cohort

## Study drug and medical condition

### **Study drug International non-proprietary name (INN) or common name**

PERINDOPRIL TERT-BUTYLAMINE

PERINDOPRIL ARGININE

INDAPAMIDE

---

### **Medical condition to be studied**

Essential hypertension

## Population studied

### **Age groups**

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

## **Estimated number of subjects**

13988

## Study design details

### **Outcomes**

Primary outcome will be SBP change between SBP at ID and the closest SBP value to week 8 in a window of 4 weeks to 24 weeks after ID. Change in DBP between DBP at ID and the closest DBP value to week 8 in a window of 4 weeks to 24 weeks after ID. SBP change between SBP at ID and the mean of all the SBP values recorded in a window of 4 weeks to 24 weeks after ID, instead of the closest record to week 8. Percentage of patients who reach BP control at week 8.

---

### **Data analysis plan**

Patients in both groups will be matched using a propensity score. The primary outcome that will be SBP change between baseline and week 8, will be assessed using a linear regression model. Missing data will be handled using multiple imputation and return-to-baseline approaches according to missing pattern. The secondary objective will further assess how BP effect of antihypertensive drugs can be measured considering real life context (less selected population, sparse BP measures). Thus, different methods like alternative definitions of population, alternative definitions of outcomes (e.g. BP control), and complementary statistical approaches (Standardized Mortality Ratio and Inverse probability censoring weighting) will be used

## Data management

## Data sources

**Data source(s)**

Clinical Practice Research Datalink

---

**Data sources (types)**

[Electronic healthcare records \(EHR\)](#)

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No